{"name":"Inmunotek S.L.","slug":"inmunotek-s-l","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"immunology","drugs":[{"name":"Biological vaccine","genericName":"Biological vaccine","slug":"biological-vaccine","indication":"Other","status":"phase_3"},{"name":"MG56 Mannosylated 3000 sublingual","genericName":"MG56 Mannosylated 3000 sublingual","slug":"mg56-mannosylated-3000-sublingual","indication":"Other","status":"phase_2"},{"name":"MG56 Mannosylated 500 subcutaneous","genericName":"MG56 Mannosylated 500 subcutaneous","slug":"mg56-mannosylated-500-subcutaneous","indication":"Other","status":"phase_2"},{"name":"MG56 Mannosylated 5000 subcutaneous","genericName":"MG56 Mannosylated 5000 subcutaneous","slug":"mg56-mannosylated-5000-subcutaneous","indication":"Other","status":"phase_2"},{"name":"MM09 Mannosylated 10.000 subcutaneous","genericName":"MM09 Mannosylated 10.000 subcutaneous","slug":"mm09-mannosylated-10-000-subcutaneous","indication":"Other","status":"phase_2"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Bactek-R","genericName":"Bactek-R","slug":"bactek-r","indication":"Recurrent respiratory tract infections","status":"phase_3"},{"name":"MV140","genericName":"MV140","slug":"mv140","indication":"Prevention of recurrent urinary tract infections in adults","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"cardiovascular","drugs":[{"name":"Clustoid® Max Forte","genericName":"Clustoid® Max Forte","slug":"clustoid-max-forte","indication":"Allergic diseases or immunological disorders (specific indication not publicly confirmed)","status":"phase_2"},{"name":"MG56 Mannosylated 1000 sublingual","genericName":"MG56 Mannosylated 1000 sublingual","slug":"mg56-mannosylated-1000-sublingual","indication":"Immune modulation for the treatment of unspecified immunological disorders","status":"phase_2"}]}],"pipeline":[{"name":"Bactek-R","genericName":"Bactek-R","slug":"bactek-r","phase":"phase_3","mechanism":"Bactek-R is a bacterial lysate immunotherapy that stimulates innate and adaptive immune responses to enhance respiratory tract defenses.","indications":["Recurrent respiratory tract infections"],"catalyst":""},{"name":"Biological vaccine","genericName":"Biological vaccine","slug":"biological-vaccine","phase":"phase_3","mechanism":"A biological vaccine that stimulates the immune system to recognize and attack disease-causing pathogens or abnormal cells.","indications":[],"catalyst":""},{"name":"Clustoid® Max Forte","genericName":"Clustoid® Max Forte","slug":"clustoid-max-forte","phase":"phase_2","mechanism":"Clustoid® Max Forte is an immunotherapeutic agent designed to modulate immune responses, likely through allergen immunotherapy or immune tolerance induction.","indications":["Allergic diseases or immunological disorders (specific indication not publicly confirmed)"],"catalyst":""},{"name":"MG56 Mannosylated 1000 sublingual","genericName":"MG56 Mannosylated 1000 sublingual","slug":"mg56-mannosylated-1000-sublingual","phase":"phase_2","mechanism":"MG56 Mannosylated 1000 sublingual is designed to enhance immune response through targeted delivery to immune cells.","indications":["Immune modulation for the treatment of unspecified immunological disorders"],"catalyst":""},{"name":"MG56 Mannosylated 3000 sublingual","genericName":"MG56 Mannosylated 3000 sublingual","slug":"mg56-mannosylated-3000-sublingual","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"MG56 Mannosylated 500 subcutaneous","genericName":"MG56 Mannosylated 500 subcutaneous","slug":"mg56-mannosylated-500-subcutaneous","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"MG56 Mannosylated 5000 subcutaneous","genericName":"MG56 Mannosylated 5000 subcutaneous","slug":"mg56-mannosylated-5000-subcutaneous","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"MM09 Mannosylated 10.000 subcutaneous","genericName":"MM09 Mannosylated 10.000 subcutaneous","slug":"mm09-mannosylated-10-000-subcutaneous","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"MV140","genericName":"MV140","slug":"mv140","phase":"phase_3","mechanism":"MV140 is a polyvalent bacterial lysate vaccine that stimulates innate and adaptive immune responses to prevent recurrent urinary tract infections.","indications":["Prevention of recurrent urinary tract infections in adults"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi0AJBVV95cUxPTWpXc3VzY3BHVkgtSzBYbE4zc2Rkenc4ZGNYUUZCenVDaEVXdGtYT1pEVWlsWjNmQnplMjNPQjdsaVRhOFdQUDN1eUdUTFQwZUxfOUIwa2NZdFJhZk5lQXZ0ZWpmQzkwY3lLb1dtSnQ2dGlWamJ2NTFhckFreFZNbmtyLXJ2T3lPeG0yMENQOFgxdEhobklMU2VHOVBLYUNyX01iVjRyOVdRZTM2WDB6MncwUk96aUM2TElVRmVDSWFpaTBIU1pXQWJWNUJCcXlsTHBwYmJXdUNDYVFPT09TeVBEaW1HZ0xqMG1MdlgxcF9YTVBRVEIyR3d3anRnTUptcGhsQktRazlzNk9HTmtTV2ZNMGNxOEw3QTR6QThFbDZUazBOekJlRlRmV3Z0b2h4ckdnYnlqMDFvU25rVVdRV1ZTaTFJVl9aZFdzOUEyM3M?oc=5","date":"2026-04-08","type":"pipeline","source":"Barchart.com","summary":"COPD Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Genentech, GlaxoSmithKline, Verona Pharma, Regeneron Pharma, Sanofi, MedImmune, EpiEndo Pharma, Tetherex Pharma, AstraZene","headline":"COPD Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Genentech, GlaxoSmithKline, Verona Pharma,","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBkMHhEUlpZV25feTRUekJKUFNmRXI2S25QMFd3SEJvYlFqOHNjeWwtdUJnUFFXMi1BUlJ4aFVSeUZaVTM5NVBub1NoOEdQYTFQR2JCdTlrbXU3cW1mS1BB?oc=5","date":"2020-09-01","type":"pipeline","source":"Nature","summary":"The next generation of allergy vaccines targeting dendritic cells - Nature","headline":"The next generation of allergy vaccines targeting dendritic cells","sentiment":"neutral"}],"patents":[],"drugCount":9,"phaseCounts":{"phase_3":3,"phase_2":6},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}